12:30  WELCOME AND INTRODUCTIONS
W Marston Linehan

PRESENTATION OF CaPCURE AWARDS
Stuart Holden

PROGRAM OVERVIEW
Christopher P Evans

12:45  PROSTATE CANCER I
Moderator: Mark S Litwin

EXCLUSION OF INFLAMMATION IN THE DIFFERENTIAL DIAGNOSIS OF AN ELEVATED PSA: CONSIDERATIONS AND EVIDENCE
William Catalona

1:00  WILLET F. WHITMORE, JR. LECTURE
INTRODUCTION
W Marston Linehan

THE SURGICAL MANAGEMENT OF LOCALIZED PROSTATE CANCER: OPPORTUNITIES AND LIMITATIONS
Peter T Scardino

1:30  PROSTATE CANCER II
Moderator: Peter R Carroll

1:30  PRIMARY THERAPY FOR INTERMEDIATE RISK PROSTATE CANCER: ANY DIFFERENCES IN OUTCOMES, QOL OR SALVAGE OPTIONS WITH SURGERY VS. RADIOTHERAPY?
Eric A Klein
1:40 DISCUSSION
Peter R Carroll

1:55 PANEL DISCUSSION: TRANSITIONAL CELL CARCINOMA I
Moderator and Panel Lead: David Wood

2:25 TRANSITIONAL CELL CARCINOMA II
Moderator: Ralph deVere White

ARE WE UNDERUTILIZING MINIMALLY INVASIVE APPROACHES FOR UPPER TRACT TCC?
J Stuart Wolf

3:10 PROSTATE CANCER III - WITH THE EVIDENCE AVAILABLE, WHAT IS THE ROLE FOR INTERMITTENT ANDROGEN BLOCKADE?
Moderator: Samir S Taneja

INTERMITTENT ANDROGEN BLOCKADE IS THE STANDARD OF CARE
Martin Gleave

CONTINUOUS AND MAXIMAL ANDROGEN BLOCKADE; ARE WE OVERTREATING?
Laurence H Klotz

3:35 RENAL CELL CARCINOMA
Robert G Uzzo

3:50 PANEL DISCUSSION: SURGERY FOR RECURRENT AND METASTATIC RENAL CELL CANCER: HAS THE ROLE CHANGED IN THE FACE OF NEW SYSTEMATIC AGENTS?
Moderator and Panel Lead: Christopher G Wood, Sr

4:05 PROSTATE CANCER IV - POST-RADICAL PROSTATECTOMY MANAGEMENT OPTIONS FOR THE POSITIVE SURGICAL MARGIN
Moderator: Joseph A Smith, Jr
ARGUMENT FOR ADJUVANT RADIOTHERAPY
Joseph L Chin

4:12 ARGUMENT FOR ANDROGEN DEPRIVATION THERAPY AND CHEMOTHERAPY
Celestia S Higano

4:19 ARGUMENT FOR OBSERVATION
Judd Moul

PROSTATE CANCER V
Moderator: Mitchell C Benson

TIMING OF TAXANE ADMINISTRATION IN ANDROGEN-INDEPENDENT PROSTATE CANCER: WHEN TO REFER AND WHEN TO TREAT
Tomasz M Beer

4:45 PANEL DISCUSSION
Panelists: Tomasz M Beer, Howard I Scher, Joel B Nelson